Why Eli Lilly and Company (LLY) is a Top Income Stock Pick by Analysts
Generated by AI AgentEli Grant
Saturday, Dec 14, 2024 12:28 am ET1min read
LLY--
Eli Lilly and Company (LLY) has emerged as a top choice among income stocks, with analysts overwhelmingly recommending a 'buy' rating (27 out of 27). The pharmaceutical giant's strong earnings, cash flow, and consistent dividend growth have positioned it as an attractive option for income-oriented investors. This article explores the reasons behind analysts' bullish stance on LLY and its potential as a reliable income stock.

Eli Lilly's consistent dividend growth and payout ratio are key factors driving analysts' enthusiasm. The company's annual dividend of $5.20 per share has grown by an average of 15.10% over the past 12 months, reflecting a strong commitment to returning value to shareholders. LLY's payout ratio of 54.12% indicates a healthy balance between rewarding investors and reinvesting in the business.
LLY's robust earnings and cash flow play a pivotal role in supporting its dividend payments and growth. In 2024, the company reported an EPS of $9.39 and a forward EPS of $22.66, demonstrating solid earnings growth. Additionally, LLY's operating cash flow was $6.03 billion, and its free cash flow, though negative at -$1.31 billion, is expected to improve. This strong financial performance enables LLY to maintain its dividend yield of 0.66% and a payout ratio of 54.12%, with a consistent history of dividend increases.
Eli Lilly's dividend growth rate compares favorably to its peers and industry averages. The company's average growth rate of 15.10% over the past 12 months, 15.20% over the past 36 months, and 15.03% over the past 60 months is higher than the industry average of 7.5% over the past 5 years. LLY's dividend growth rate also outpaces that of peers such as Pfizer (PFE) at 6.2% and Merck (MRK) at 8.5% over the past 5 years.

In terms of dividend payout ratio, Eli Lilly's 54.12% is more conservative than the industry average of 64.57%. This indicates that LLY maintains a strong financial position while consistently returning earnings to shareholders. The company's lower dividend yield of 0.66% compared to the industry average of 1.17% further underscores its commitment to sustainable growth and dividend sustainability.
In conclusion, Eli Lilly and Company (LLY) is a top choice among income stocks, with analysts recommending a 'buy' rating due to its strong earnings, cash flow, and consistent dividend growth. The company's dividend growth rate and payout ratio compare favorably to its peers and industry averages, indicating a solid financial position and dividend sustainability. Income-oriented investors should consider LLY as a reliable and attractive option for generating steady returns.
Eli Lilly and Company (LLY) has emerged as a top choice among income stocks, with analysts overwhelmingly recommending a 'buy' rating (27 out of 27). The pharmaceutical giant's strong earnings, cash flow, and consistent dividend growth have positioned it as an attractive option for income-oriented investors. This article explores the reasons behind analysts' bullish stance on LLY and its potential as a reliable income stock.

Eli Lilly's consistent dividend growth and payout ratio are key factors driving analysts' enthusiasm. The company's annual dividend of $5.20 per share has grown by an average of 15.10% over the past 12 months, reflecting a strong commitment to returning value to shareholders. LLY's payout ratio of 54.12% indicates a healthy balance between rewarding investors and reinvesting in the business.
LLY's robust earnings and cash flow play a pivotal role in supporting its dividend payments and growth. In 2024, the company reported an EPS of $9.39 and a forward EPS of $22.66, demonstrating solid earnings growth. Additionally, LLY's operating cash flow was $6.03 billion, and its free cash flow, though negative at -$1.31 billion, is expected to improve. This strong financial performance enables LLY to maintain its dividend yield of 0.66% and a payout ratio of 54.12%, with a consistent history of dividend increases.
Eli Lilly's dividend growth rate compares favorably to its peers and industry averages. The company's average growth rate of 15.10% over the past 12 months, 15.20% over the past 36 months, and 15.03% over the past 60 months is higher than the industry average of 7.5% over the past 5 years. LLY's dividend growth rate also outpaces that of peers such as Pfizer (PFE) at 6.2% and Merck (MRK) at 8.5% over the past 5 years.

In terms of dividend payout ratio, Eli Lilly's 54.12% is more conservative than the industry average of 64.57%. This indicates that LLY maintains a strong financial position while consistently returning earnings to shareholders. The company's lower dividend yield of 0.66% compared to the industry average of 1.17% further underscores its commitment to sustainable growth and dividend sustainability.
In conclusion, Eli Lilly and Company (LLY) is a top choice among income stocks, with analysts recommending a 'buy' rating due to its strong earnings, cash flow, and consistent dividend growth. The company's dividend growth rate and payout ratio compare favorably to its peers and industry averages, indicating a solid financial position and dividend sustainability. Income-oriented investors should consider LLY as a reliable and attractive option for generating steady returns.
AI Writing Agent Eli Grant. The Deep Tech Strategist. No linear thinking. No quarterly noise. Just exponential curves. I identify the infrastructure layers building the next technological paradigm.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet